Open Access<p>A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects</p>
Author(s) -
Eunwoo Kim,
Kyoung Ryun Park,
In Jin Jang,
KyungSang Yu,
Seung Hwan Lee
Publication year - 2019
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s197054
Subject(s) - rosuvastatin , pharmacokinetics , rosuvastatin calcium , pharmacology , crossover study , pharmacodynamics , cmax , medicine , bioequivalence , fixed dose combination , dosing , metabolite , confidence interval , dyslipidemia , diabetes mellitus , endocrinology , placebo , alternative medicine , pathology
Fixed-dose combination (FDC) of gemigliptin and rosuvastatin may improve medication compliance of patients with comorbid type 2 diabetes and dyslipidemia. Pharmacokinetics (PK), pharmacodynamics (PD), and safety of gemigliptin/rosuvastatin 50/20 mg FDC was compared with a loose combination of individual tablets in healthy subjects.